• Our Company

QuintilesIMS Delivers Integrated Information and Technology Solutions to Drive Healthcare Forward

Around the world healthcare stakeholders are working to improve real-world patient outcomes through treatment innovations, care provision and access to healthcare. For the information, technology and service solutions they need to drive new insights and approaches, they count on QuintilesIMS. With a global team of 50,000, we harness insights, commercial and scientific depth, and executional expertise to empower clients to achieve some of their most important goals: Improving clinical, scientific and commercial results. Realizing the full potential of innovations. And, ultimately, driving healthcare forward.

For more information please visit www.quintilesims.com.

Driving Healthcare Performance in Malaysia

History
Established in Malaysia in the early the 1980s, QuintilesIMS Malaysia has one of the most comprehensive offering portfolios in the region, with its solutions for the life sciences industry including the Malaysia Pharmaceutical Audit with post code level data. In 2003, QuintilesIMS introduced the Malaysia Tender (MTD) report and Malaysia Institution Report (MGV), allowing the industry to have a consolidated view of the Government Pharmaceutical procurement. In 2008, these evolved into the Malaysia Government Report which now gives a consolidated view of the overall Pharmaceutical Market. IMS Malaysia made a significant investment to help clients track the performance of the market in 2012, with the introduction of the Malaysia Distributors Pharmaceutical Index (MDPI), where performance of the market could be monitored on a monthly basis. The introduction of Consumer Healthcare Analysis Malaysia (CHAM) follows in 2013 with an innovative dashboard focused primarily on OTC and Consumer Healthcare products with defined Consumer Health categories.

Market Overview
The size of the total pharmaceutical market in Malaysia reached US$1.6 billion in 2013, reflecting a 7.0% market growth from the previous year. This level of growth is expected to continue, averaging a CAGR of 8.6% up to 2018.

Malaysia’s healthcare infrastructure continues to evolve, driven by the government’s continuing five-year plans. The government is actively promoting disease prevention and the adoption of a healthy lifestyle, and improving healthcare access to address the rapidly growing incidence of chronic non-communicable diseases. Expansion of the private hospital sector, helped by liberalization of foreign investment in the sector and encouragement of medical tourism and the medical travel industry, presents further growth opportunity.

Government cost-containment measures through the promotion of generics, the closer monitoring of drug prices and changes to the pricing system, as well as the proposed implementation of pharmacoeconomic evaluation for listing on the MoH Formulary, all present challenges.

In today's highly competitive and complex environment, contact your QuintilesIMS representative to gain greater clarity and stay one step ahead of the competition with the valuable insights gained from QuintilesIMS offerings.